Immunotherapy plus chemotherapy before bladder cancer surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 with good overall health (able to walk and do light activities)
- Bladder cancer confirmed by biopsy, advanced or high-risk type, and has not spread to other organs
- Fit enough to have bladder removal surgery and tolerate strong chemotherapy
- Good kidney, liver, heart, and bone marrow function based on recent blood tests
- No prior chemotherapy, immunotherapy, or other systemic cancer treatments for bladder cancer
- Willing to use effective birth control for 6 months after treatment (applies to women and men with female partners of childbearing age)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This trial tests a combination of two drugs—vedisertib (RC48) and toripalimab—for people with bladder cancer that has invaded the muscle but hasn't spread. The goal is to preserve the bladder while treating the cancer.
This trial tests a combination of a targeted drug (disitamab vedotin) and an immunotherapy (toripalimab) before surgery for bladder cancer that has grown into the muscle. The goal is to see if this combination works better than the standard chemotherapy plus immunotherapy approach.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (gemcitabine) given directly into the bladder after surgery to remove high-risk bladder tumors. The goal is to reduce the chance of the cancer coming back.
Hear when a new Muscle-Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.